Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2021 > FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Read also

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

Lupin's Bioresearch Center Aces U.S. FDA Inspection with Zero Observations

Lupin's Bioresearch Center Aces U.S. FDA Inspection with Zero Observations

Lupin Limited, a global pharmaceutical leader, has announced a significant milestone for its Bioresearch Center in Pune.

FDA warns 18 websites for selling fake Botox linked to injuries

FDA warns 18 websites for selling fake Botox linked to injuries

U.S. regulators have issued warnings to 18 websites that were selling fake or unapproved versions of Botox and similar wrinkle-relaxing injections.

Sana, CAMP4

Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates.